Cell-based therapy in cardiac regeneration: An overview

Circulation Research

Volumn 123, Issue 2, 2018, Pages 132-137

  Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bone marrow; Editorials; Heart failure; Myocardial infarction; Regeneration; Umbilical cord

Indexed keywords

CD34 ANTIGEN;

BMSC CELL LINE; CARDIAC REGENERATION; CELL FUNCTION; CELL THERAPY; EXOSOME; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; INTRACORONARY DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; ADVERSE EVENT; ANIMAL; CLASSIFICATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; HEART DISEASE; META ANALYSIS (TOPIC); PROCEDURES; REGENERATIVE MEDICINE; STEM CELL;

ANIMALS; CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; META-ANALYSIS AS TOPIC; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 85056518304     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.118.313484     Document Type: Review

References (68)

1. Marelli D, Desrosiers C, El-Alfy M, Kao RL, Chiu RC. Cell transplantation for myocardial repair: an experimental approach. Cell Transplant. 1992;1:383-390.
2. Reinlib L, Field L. Cell transplantation as future therapy for cardiovascular disease? A workshop of the National Heart, Lung, and Blood Institute. Circulation. 2000;101:E182-E187.
3. Menasché P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagège AA. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117:1189-1200. doi: 10.1161/CIRCULATIONAHA.107.734103.
4. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM; REPAIR-AMI Investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221. doi: 10.1056/NEJMoa060186.
5. Assmus B, Honold J, Schächinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med. 2006;355:1222-1232. doi: 10.1056/NEJMoa051779.
6. Banerjee M, Bolli R, Hare J. Clinical studies of cell therapy in cardiovascular medicine: Recent developments and future directions. Circ Res. 2018;123:266-287.
7. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
8. Chen SL, Fang WW, Qian J, Ye F, Liu YH, Shan SJ, Zhang JJ, Lin S, Liao LM, Zhao RC. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl). 2004;117:1443-1448.
9. Zimmet JM, Hare JM. Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Res Cardiol. 2005;100:471-481. doi: 10.1007/s00395-005-0553-4.
10. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379. doi: 10.1001/jama.2012.25321.
11. Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017;69:526-537. doi: 10.1016/j.jacc.2016.11.009.
12. Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, Haack-Sørensen M, Ekblond A, Kastrup J. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015;36:1744-1753. doi: 10.1093/eurheartj/ehv136.
13. Bartolucci J, Verdugo FJ, González PL, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase = randomized controlled trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121:1192-1204. doi: 10.1161/CIRCRESAHA.117.310712.
14. Sussman M, Broughton K. Enhancement strategies for cardiac regenerative cell therapy: Focus on adult stem cells. Circ Res. 2018;123:177-187.
15. Gonzalez-King H, García NA, Ontoria-Oviedo I, Ciria M, Montero JA, Sepïlveda P. Hypoxia inducible factor-1α potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes. Stem Cells. 2017;35:1747-1759. doi: 10.1002/stem.2618.
16. Bartunek J, Terzic A, Davison BA, et al; CHART Program. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38:648-660. doi: 10.1093/eurheartj/ehw543.
17. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010;56:721-734. doi: 10.1016/j.jacc.2010.03.066.
18. Natsumeda M, Florea V, Rieger AC, et al. A combination of allogeneic stem cells promotes cardiac regeneration. J Am Coll Cardiol. 2017;70:2504-2515. doi: 10.1016/j.jacc.2017.09.036.
19. Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A; ixCELL-DCM Investigators. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016;387:2412-2421. doi: 10.1016/S0140-6736(16)30137-4.
20. Tokita Y, Tang XL, Li Q, Wysoczynski M, Hong KU, Nakamura S, Wu WJ, Xie W, Li D, Hunt G, Ou Q, Stowers H, Bolli R. Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy. Circ Res. 2016;119:635-651. doi: 10.1161/CIRCRESAHA.116.308937.
21. Guo Y, Wysoczynski M, Nong Y, Tomlin A, Zhu X, Gumpert AM, Nasr M, Muthusamy S, Li H, Book M, Khan A, Hong KU, Li Q, Bolli R. Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction. Basic Res Cardiol. 2017;112:18. doi: 10.1007/s00395-017-0606-5.
22. Wysoczynski M, Khan A, Bolli R. New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types. Circ Res. 2018;123:138-158.
23. Zhang J, Zhu W, Radisic M, Vunjak-Novakovic G. Can we engineer a human cardiac patch for therapy? Circ Res. 2018;123:244-265.
24. Vagnozi R, Molkentin, Houser S. New myocyte formation in the adult heart: Endogenous sources and therapeutic implications. Circ Res. 2018;123:159-176.
25. Yanamandala M, Zhu W, Garry DJ, Kamp TJ, Hare JM, Jun HW, Yoon YS, Bursac N, Prabhu SD, Dorn GW II, Bolli R, Kitsis RN, Zhang J. Overcoming the roadblocks to cardiac cell therapy using tissue engineering. J Am Coll Cardiol. 2017;70:766-775. doi: 10.1016/j.jacc.2017.06.012.
26. Gao L, Gregorich ZR, Zhu W, Mattapally S, Oduk Y, Lou X, Kannappan R, Borovjagin AV, Walcott GP, Pollard AE, Fast VG, Hu X, Lloyd SG, Ge Y, Zhang J. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine. Circulation. 2018;137:1712-1730. doi: 10.1161/CIRCULATIONAHA.117.030785.
27. Mathieu E, Lamirault G, Toquet C, Lhommet P, Rederstorff E, Sourice S, Biteau K, Hulin P, Forest V, Weiss P, Guicheux J, Lemarchand P. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One. 2012;7:e51991. doi: 10.1371/journal.pone.0051991.
28. Kissel CK, Lehmann R, Assmus B, Aicher A, Honold J, Fischer-Rasokat U, Heeschen C, Spyridopoulos I, Dimmeler S, Zeiher AM. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol. 2007;49:2341-2349. doi: 10.1016/j.jacc.2007.01.095.
29. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93-98.
30. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428:664-668. doi: 10.1038/nature02446.
31. Tang XL, Li Q, Rokosh G, Sanganalmath SK, Chen N, Ou Q, Stowers H, Hunt G, Bolli R. Long-term outcome of administration of c-kit(POS) cardiac progenitor cells after acute myocardial infarction: transplanted cells do not become cardiomyocytes, but structural and functional improvement and proliferation of endogenous cells persist for at least one year. Circ Res. 2016;118:1091-1105. doi: 10.1161/CIRCRESAHA.115.307647.
32. Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, Tio FO, Weissman NJ, Leon MB, Epstein SE, Kornowski R. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol. 2001;37:1726-1732.
33. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109:1543-1549. doi: 10.1161/01.CIR.0000124062.31102.57.
34. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367-368. doi: 10.1038/nm0405-367.
35. + stem cells in a nonhuman primate model. Stem Cells. 2005;23:355-364. doi: 10.1634/stemcells.2004-0200.
36. Ye L, Chang Y-H, Ge Y, Chang J. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cellderived cardiovascular cells. Cell Stem Cell. 2014;15:750-761.
37. Kishore R, Khan M. More than tiny sacks: stem cell exosomes as cellfree modality for cardiac repair. Circ Res. 2016;118:330-343. doi: 10.1161/CIRCRESAHA.115.307654.
38. Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164:1226-1232. doi: 10.1016/j.cell.2016.01.043.
39. Garikipati V, Shoja-Taheri F, Davis M, Kishore R. Extracellular vesicles for cardiac repair. Circ Res. 2018;123:188-204.
40. Ibrahim A, Marbán E. Exosomes: fundamental biology and roles in cardiovascular physiology. Annu Rev Physiol. 2016;78:67-83. doi: 10.1146/annurev-physiol-021115-104929.
41. Sahoo S, Klychko E, Thorne T, Misener S, Schultz KM, Millay M, Ito A, Liu T, Kamide C, Agrawal H, Perlman H, Qin G, Kishore R, Losordo DW. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res. 2011;109:724-728. doi: 10.1161/CIRCRESAHA.111.253286.
42. Arslan F, Lai RC, Smeets MB, Akeroyd L, Choo A, Aguor EN, Timmers L, van Rijen HV, Doevendans PA, Pasterkamp G, Lim SK, de Kleijn DP. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10:301-312. doi: 10.1016/j.scr.2013.01.002.
43. Gallet R, Dawkins J, Valle J, Simsolo E, de Couto G, Middleton R, Tseliou E, Luthringer D, Kreke M, Smith RR, Marbán L, Ghaleh B, Marbán E. Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2017;38:201-211. doi: 10.1093/eurheartj/ehw240.
44. Zhao Y, Sun X, Cao W, Ma J, Sun L, Qian H, Zhu W, Xu W. Exosomes derived from human umbilical cord mesenchymal stem cells relieve acute myocardial ischemic injury. Stem Cells Int. 2015;2015:761643. doi: 10.1155/2015/761643.
45. + stem cell exosomes in the repair of ischemic hindlimb. Circ Res. 2017;120:1466-1476. doi: 10.1161/CIRCRESAHA.116.310557.
46. Yeo RW, Lai RC, Zhang B, Tan SS, Yin Y, Teh BJ, Lim SK. Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2013;65:336-341. doi: 10.1016/j.addr.2012.07.001.
47. Chen TS, Arslan F, Yin Y, Tan SS, Lai RC, Choo AB, Padmanabhan J, Lee CN, de Kleijn DP, Lim SK. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J Transl Med. 2011;9:47. doi: 10.1186/1479-5876-9-47.
48. Silvestre JS, Menasché P. The evolution of the stem cell theory for heart failure. EBioMedicine. 2015;2:1871-1879. doi: 10.1016/j.ebiom.2015.11.010.
49. Bittle G, Morales D, Deatrick K, et al. Cell therapy for congenital heart disease stem cell therapy for hypoplastic left heart syndrome: Mechanism, clinical application, and future directions. Circ Res. 2018;123:288-300.
50. Mishra R, Vijayan K, Colletti EJ, Harrington DA, Matthiesen TS, Simpson D, Goh SK, Walker BL, Almeida-Porada G, Wang D, Backer CL, Dudley SC Jr, Wold LE, Kaushal S. Characterization and functionality of cardiac progenitor cells in congenital heart patients. Circulation. 2011;123:364-373. doi: 10.1161/CIRCULATIONAHA.110.971622.
51. Sharma S, Mishra R, Bigham GE, et al. A deep proteome analysis identifies the complete secretome as the functional unit of human cardiac progenitor cells. Circ Res. 2017;120:816-834. doi: 10.1161/CIRCRESAHA.116.309782.
52. Agarwal U, George A, Bhutani S, Ghosh-Choudhary S, Maxwell JT, Brown ME, Mehta Y, Platt MO, Liang Y, Sahoo S, Davis ME. Experimental, systems, and computational approaches to understanding the microRNA-mediated reparative potential of cardiac progenitor cellderived exosomes from pediatric patients. Circ Res. 2017;120:701-712. doi: 10.1161/CIRCRESAHA.116.309935.
53. Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem cell therapy for congenital heart disease: a systematic review. Circulation. 2017;136:2373-2385. doi: 10.1161/CIRCULATIONAHA.117.029607.
54. Davies B, Elwood NJ, Li S, Cullinane F, Edwards GA, Newgreen DF, Brizard CP. Human cord blood stem cells enhance neonatal right ventricular function in an ovine model of right ventricular training. Ann Thorac Surg. 2010;89:585-593, 593.e1. doi: 10.1016/j.athoracsur.2009.10.035.
55. Wehman B, Sharma S, Pietris N, Mishra R, Siddiqui OT, Bigham G, Li T, Aiello E, Murthi S, Pittenger M, Griffith B, Kaushal S. Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload. Am J Physiol Heart Circ Physiol. 2016;310:H1816-H1826. doi: 10.1152/ajpheart.00955.2015.
56. Yerebakan C, Sandica E, Prietz S, et al. Autologous umbilical cord blood mononuclear cell transplantation preserves right ventricular function in a novel model of chronic right ventricular volume overload. Cell Transplant. 2009;18:855-868. doi: 10.3727/096368909X471170.
57. Ishigami S, Ohtsuki S, Eitoku T, et al. Intracoronary cardiac progenitor cells in single ventricle physiology: the PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease) randomized phase 2 trial. Circ Res. 2017;120:1162-1173. doi: 10.1161/CIRCRESAHA.116.310253.
58. Gyongyosi M, Haller P, Blake D, Martin-Rendon E. Meta-analysis of cell therapy studies in acute myocardial infarction and heart failure. Circ Res. 2018;123:301-308.
59. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive metaanalyses may be inconclusive-trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009;38:287-298. doi: 10.1093/ije/dyn188.
60. Fisher SA, Doree C, Taggart DP, Mathur A, Martin-Rendon E. Cell therapy for heart disease: trial sequential analyses of two Cochrane reviews. Clin Pharmacol Ther. 2016;100:88-101. doi: 10.1002/cpt.344.
61. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016;12:CD007888. doi: 10.1002/14651858.CD007888.pub3.
62. Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015;(2):CD006536. doi: 10.1002/14651858.CD006536.pub3.
63. Gyöngyösi M, Wojakowski W, Lemarchand P, et al.; ACCRUE Investigators. Meta-analysis of cell-based Cardiac studies (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116:1346-1360. doi: 10.1161/CIRCRESAHA. 116.304346.
64. Xu JY, Liu D, Zhong Y, Huang RC. Effects of timing on intracoronary autologous bone marrow-derived cell transplantation in acute myocardial infarction: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2017;8:231. doi: 10.1186/s13287-017-0680-5.
65. Mathur A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, Janssens S, Menasché P, Wojakowski W, Martin JF, Zeiher A. The consensus of the task force of the European Society of Cardiology. Eur Heart J. 2017;38:2930-2935.
66. Madonna R, Van Laake LW, Davidson SM, et al. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J. 2016;37:1789-1798. doi: 10.1093/eurheartj/ehw113.
67. + cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials [published online ahead of print January 5, 2018]. Eur Heart J. doi: 10.1093/eurheartj/ehx764.
68. Fernandez-Aviles F, Sanz-Ruiz R, Climent AM, et al. Global position paper on cardiovascular regenerative medicine. Eur Heart J. 2017;38:2532-2546.